Anthracycline-induced cardiomyopathy in children: a report of six cases.
Although anthracycline antibiotics are among the most useful chemotherapy agents, the risk of producing cardiomyopathy and the absence of a reliable noninvasive technique to predict subclinical cardiomyopathy remain a major problem. We retrospectively reviewed our experience with anthracyclines over a 5-year period. Cardiomyopathy developed in 6 of 112 patients (5.3%) treated with anthracyclines and was fatal in 5 of the 6 patients. Our incidence and mortality rates are higher than those previously reported.
D000293:Adolescent; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000401:mortality / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D003630:Daunorubicin / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D009206:Myocardium / Q000473:pathology; D009279:Naphthacenes / Q000009:adverse effects; D012189:Retrospective Studies
D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; D004317:Doxorubicin; D003630:Daunorubicin